PharmiWeb.com - Global Pharma News & Resources
02-Apr-2019

BD Presents Research at 24th EAHP Congress That Shows Increased Patient Safety, and Cost and Time Savings With Pre-filled Syringes in the Acute Care Setting

BD (Becton, Dickinson and Company), has presented research at EAHP showing that in the acute care setting, the use of pre-filled syringes (PFS) provides increased patient safety and institutional cost savings compared to use of vials and syringes.1 The results of their targeted literature review will be presented at the 24th Congress of the European Association of Hospital Pharmacists (EAHP), being held from March 27 to March 29, 2019.

The research showed that vial and syringe use was 17 times more likely to lead to medication errors compared to using PFS.2 The results also demonstrate the multifactorial benefits associated with the use of PFS in the acute care setting including reduced medication preparation time, a lower risk of adverse events and reduced medication wastage.1 Pre-filled syringe use also reduced preparation time and associated labor costs by 43.5% compared to vials and syringes.2

 

Alfred Harvey, associate director, HEOR, BD commented: “With medication errors occurring at an alarming rate, coupled to continued pressure on health care resources, it is important that drug preparation and administration methods are reviewed to help enhance patient safety and the efficiency of care delivery. This research shows that increased patient safety and long-term cost and resource savings can be achieved by using PFS compared to the traditional vial and syringe method of administering drugs in the acute care setting.”

 

The research was based on a targeted literature review conducted by BD to understand the impact of drug administration using PFS compared to conventional vials and syringes on patient safety, supply costs, cost savings and time savings. The review included eight studies, the majority of which were conducted in the United States and United Kingdom.

 

About BD

BD is one of the largest global medical technology companies and is advancing health care by improving medical discovery, diagnostics and care delivery. The company supports the heroes that work on the frontline by developing innovative technology, services and solutions, to advance clinical therapy for patients and clinical process for health care providers. BD and its 65,000 employees have a passion and commitment to help enhance the safety and efficiency of clinicians' care delivery process, enable laboratory scientists to accurately detect disease and advance researchers' capabilities to develop the next generation of diagnostics and therapeutics. BD has a presence in virtually every country and partners with organizations around the world to address some of the most challenging global health issues. By working in close collaboration with customers, BD can help enhance outcomes, lower costs, increase efficiencies, improve safety and expand access to health care. In 2017, BD welcomed C. R. Bard and its products into the BD family. For more information on BD, please visit bd.com.   

 

For further information:

Troy Kirkpatrick                                                     Monique N. Dolecki
BD Public Relations                                                BD Investor Relations
858.617.2361                                                       201.847.5378

troy.kirkpatrick@bd.com                                        monique_dolecki@bd.com

 

References

  1. Osman N, et al. Characterisation of prefilled syringe use in an acute care setting: costs and advantages. Poster presented at 24th Congress of the European Association of Hospital Pharmacists (EAHP), 2019.
  2. Adapa RM, et al. Errors during the preparation of drug infusions: a randomized controlled trial. Br J Anaesth. 2012;109(5):729-734.

 

BD (Becton, Dickinson and Company), a leading global medical technology company, is to present research showing that in the acute care setting, the use of pre-filled syringes (PFS) provides increased patient safety and institutional cost savings compared to use of vials and syringes.1 The results of their targeted literature review will be presented at the 24th Congress of the European Association of Hospital Pharmacists (EAHP), being held from March 27 to March 29, 2019.

 

The research showed that vial and syringe use was 17 times more likely to lead to medication errors compared to using PFS.2 The results also demonstrate the multifactorial benefits associated with the use of PFS in the acute care setting including reduced medication preparation time, a lower risk of adverse events and reduced medication wastage.1 Pre-filled syringe use also reduced preparation time and associated labor costs by 43.5% compared to vials and syringes.2

 

Alfred Harvey, associate director, HEOR, BD commented: “With medication errors occurring at an alarming rate, coupled to continued pressure on health care resources, it is important that drug preparation and administration methods are reviewed to help enhance patient safety and the efficiency of care delivery. This research shows that increased patient safety and long-term cost and resource savings can be achieved by using PFS compared to the traditional vial and syringe method of administering drugs in the acute care setting.”

 

The research was based on a targeted literature review conducted by BD to understand the impact of drug administration using PFS compared to conventional vials and syringes on patient safety, supply costs, cost savings and time savings. The review included eight studies, the majority of which were conducted in the United States and United Kingdom.

 

About BD

BD is one of the largest global medical technology companies and is advancing health care by improving medical discovery, diagnostics and care delivery. The company supports the heroes that work on the frontline by developing innovative technology, services and solutions, to advance clinical therapy for patients and clinical process for health care providers. BD and its 65,000 employees have a passion and commitment to help enhance the safety and efficiency of clinicians' care delivery process, enable laboratory scientists to accurately detect disease and advance researchers' capabilities to develop the next generation of diagnostics and therapeutics. BD has a presence in virtually every country and partners with organizations around the world to address some of the most challenging global health issues. By working in close collaboration with customers, BD can help enhance outcomes, lower costs, increase efficiencies, improve safety and expand access to health care. In 2017, BD welcomed C. R. Bard and its products into the BD family. For more information on BD, please visit bd.com.   

 

For further information:

Troy Kirkpatrick                                                     Monique N. Dolecki
BD Public Relations                                                BD Investor Relations
858.617.2361                                                       201.847.5378

troy.kirkpatrick@bd.com                                        monique_dolecki@bd.com

 

References

  1. Osman N, et al. Characterisation of prefilled syringe use in an acute care setting: costs and advantages. Poster presented at 24th Congress of the European Association of Hospital Pharmacists (EAHP), 2019.
  2. Adapa RM, et al. Errors during the preparation of drug infusions: a randomized controlled trial. Br J Anaesth. 2012;109(5):729-734.

 

Editor Details

Last Updated: 02-Apr-2019